Filing Analysis
Inovio Pharmaceuticals, Inc. issued an 8-K to furnish its quarterly financial results for the period ended June 30, 2026. The filing serves as a formal announcement of the company's recent earnings release.
📋 Key Facts
- Report date: August 12, 2026
- Reporting period: Quarter ended June 30, 2026
- The filing includes Exhibit 99.1, which contains the full press release of financial results.
- Information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 liability.
Inovio Pharmaceuticals announced a public offering of common stock and warrants to raise approximately $18.3 million in net proceeds. The offering includes significant dilution through the issuance of over 21 million shares and accompanying warrants.
🚩 Red Flags
- Significant dilution: The number of issuable shares via warrants (42M+) is nearly double the amount of common stock being offered in this round.
- Low offering price relative to potential exercise prices suggests a highly dilutive capital raise typical of distressed micro-cap financing.
- Warrant overhang: The massive volume of warrants issued can create significant downward pressure on the stock price upon exercise.
📋 Key Facts
- Public offering of 21,052,632 shares of Common Stock and accompanying warrants to purchase up to 42,105,264 shares (or pre-funded warrants).
- Combined public offering price: $0.95 per share of Common Stock and accompanying Warrant.
- Warrant exercise price: $1.10 per share ($1.099 for Pre-Funded Warrants).
- Expected net proceeds: approximately $18.3 million after discounts, commissions, and expenses.
- Underwriter (Piper Sandler & Co.) exercised an option to purchase additional warrants for 6,315,788 shares/pre-funded warrants.
- Warrants expire five years from the date of issuance.
Inovio Pharmaceuticals provided preliminary unaudited cash and cash equivalents information for the quarter ended June 30, 2026. The company reports an estimated cash position of approximately $36.7 million.
🚩 Red Flags
- Preliminary/unaudited nature of the reported cash position may be subject to adjustment during final closing procedures.
📋 Key Facts
- As of June 30, 2026, estimated cash and cash equivalents: ~$36.7 million.
- Financial data is preliminary, unaudited, and based on management estimates.
- The information is subject to completion of financial closing procedures.
Inovio Pharmaceuticals, Inc. amended its bylaws to enhance corporate governance practices, including establishing a Lead Independent Director role. The company also reported the voting results from its 2026 Annual Meeting of Stockholders, where all proposals were approved.
📋 Key Facts
- On May 19, 2026, the Board approved an amendment to the bylaws to clarify that the Chairman is not an officer unless designated, and to establish a Lead Independent Director position.
- A Lead Independent Director is now required if the Chief Executive Officer also serves as Chairman of the Board.
- At the Annual Meeting on May 20, 2026, 58.57% of eligible shares (40,670,629 shares) were represented.
- Stockholders elected eight directors, ratified Ernst & Young LLP as the independent auditor for 2026, approved executive compensation, and approved the amendment of the 2023 Omnibus Incentive Plan.
Inovio Pharmaceuticals reported its financial results for the first quarter ended March 31, 2026. The filing serves as a formal notice of the earnings release and includes the press release as an exhibit.
📋 Key Facts
- The filing was made on May 13, 2026.
- The financial results cover the quarter ended March 31, 2026.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- Exhibit 99.1 contains the full press release detailing the financial performance.
Inovio Pharmaceuticals entered into an underwriting agreement for a public offering of 12.5 million shares and 25 million warrants, expected to raise approximately $16 million in net proceeds. The offering is highly dilutive, featuring a 200% warrant coverage with exercise prices set at the offering price of $1.40.
🚩 Red Flags
- Extreme dilution: The 25 million warrants represent 200% coverage relative to the 12.5 million shares offered.
- Warrant exercise price ($1.40) is not at a premium to the offering price.
- Relatively small capital raise ($16M) for a biotech company, potentially indicating a limited cash runway.
📋 Key Facts
- Offering of 12,500,000 shares of common stock (or pre-funded warrants) at $1.40 per unit.
- Includes 12,500,000 Series A Warrants (1-year term) and 12,500,000 Series B Warrants (5-year term).
- Warrants are exercisable immediately at $1.40 per share.
- Net proceeds estimated at $16 million after fees and expenses.
- Underwriters (Piper Sandler & Co.) granted a 30-day option to purchase an additional 1,875,000 shares and associated warrants.
- Closing expected on or about April 6, 2026.
Inovio Pharmaceuticals has suspended and terminated its prospectus for an at-the-market (ATM) offering program with Oppenheimer & Co. Inc. as of April 1, 2026. While the underlying sales agreement remains in effect, the company cannot resume share sales until a new prospectus is filed.
📋 Key Facts
- The ATM prospectus dated August 13, 2024, was suspended and terminated on April 1, 2026.
- As of the suspension date, the company had sold 1,319,644 shares for gross proceeds of $3.2 million.
- The Sales Agreement with Oppenheimer & Co. Inc. remains in full force and effect.
- No further sales of common stock will occur under this program until a new prospectus is filed.
Inovio Pharmaceuticals, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025. The disclosure was made via a press release furnished under Item 2.02 of Form 8-K.
📋 Key Facts
- Reporting period: Quarter and full year ended December 31, 2025
- Filing date: March 12, 2026
- Information furnished under Item 2.02 (Results of Operations and Financial Condition)
- Exhibit 99.1 contains the full press release detailing financial performance
Inovio Pharmaceuticals amended its outstanding Series A Warrants to extend their expiration date from January 28, 2026, to March 31, 2026. This extension is linked to the timing of the FDA acceptance of a Biologic License Application (BLA) for INO-3107.
🚩 Red Flags
- Potential dilution: The extension involves over 13.5 million shares, which could lead to significant shareholder dilution upon exercise.
- Dependency on regulatory milestones: The warrant terms are explicitly tied to FDA BLA acceptance for INO-3107.
📋 Key Facts
- Amendment extends expiration of Series A Warrants from Jan 28, 2026, to March 31, 2026.
- Series A Warrants are exercisable for up to 13,564,268 shares of common stock (or pre-funded warrants).
- Exercise price is $1.75 per share ($1.749 for pre-funded warrants).
- The original expiration was tied to a 30-day window following the FDA acceptance of the INO-3107 BLA.
Inovio Pharmaceuticals announced that the FDA has accepted its Biologic License Application (BLA) for INO-3107 to treat recurrent respiratory papillomatosis (RRP). While the application was accepted under an accelerated approval pathway, the FDA raised a potential issue regarding the adequacy of data to justify this specific pathway.
🚩 Red Flags
- Potential regulatory hurdle: FDA preliminary conclusion that data may not support 'accelerated approval' eligibility, which could force a shift to a traditional pathway (longer timeline/higher burden of proof).
- Significant time gap until PDUFA date (October 2026).
📋 Key Facts
- FDA accepted BLA for INO-3107 for the treatment of RRP in adults.
- Review classification: Standard.
- PDUFA goal date set for October 30, 2026.
- The FDA is not currently planning an advisory committee meeting.
- The application was filed under the accelerated approval pathway.
- FDA noted a potential review issue regarding whether the company has submitted adequate information to justify eligibility for accelerated approval.
Inovio Pharmaceuticals, Inc. entered into an underwriting agreement to conduct a public offering of 13,158,000 shares at $1.90 per share. The underwriters fully exercised their over-allotment option, bringing total expected net proceeds to approximately $26.5 million.
🚩 Red Flags
- Significant equity dilution: Issuance of over 13 million new shares at a low price point ($1.90) will significantly dilute existing shareholders.
- Capital raise necessity: The scale of the offering suggests a need for immediate liquidity to fund operations.
📋 Key Facts
- Public offering of 13,158,000 shares of common stock.
- Offering price set at $1.90 per share.
- Underwriters fully exercised an option to purchase up to 1,973,700 additional shares on November 11, 2025.
- Expected net proceeds are approximately $26.5 million after discounts and expenses.
- The offering is being conducted via a Form S-3 registration statement declared effective January 31, 2024.
- Closing of the offering is expected on or about November 12, 2025.
Inovio Pharmaceuticals, Inc. has filed an 8-K to furnish its quarterly earnings press release for the period ended September 30, 2025.
📋 Key Facts
- The filing is a standard announcement of financial results for the quarter ended September 30, 2025.
- The report was filed on November 10, 2025.
- Information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Inovio Pharmaceuticals, Inc. filed an 8-K to furnish its quarterly earnings press release for the period ended June 30, 2025. This is a routine regulatory filing used to disclose financial results.
📋 Key Facts
- The filing was made on August 12, 2025.
- The report covers financial results for the quarter ended June 30, 2025.
- The company furnished a press release as Exhibit 99.1 containing the earnings data.
Inovio Pharmaceuticals announced a public offering of 14,285,715 shares of common stock and accompanying Series A and B warrants at $1.75 per share. The offering is expected to net approximately $22.5 million in proceeds to fund company operations.
🚩 Red Flags
- Significant dilution: Issuance of over 14 million new shares and accompanying warrants will significantly dilute existing shareholders.
- Warrant structure: The inclusion of Series A and B warrants at a low exercise price ($1.75) is characteristic of highly dilutive financing common in micro-cap biotech companies facing liquidity needs.
📋 Key Facts
- Offering size: 14,285,715 shares of common stock plus accompanying Series A and B warrants.
- Pricing: Combined public offering price of $1.75 per share/warrant unit.
- Expected net proceeds: Approximately $22.5 million (after discounts and expenses).
- Series A Warrants: Expire 12 months from issuance or 30 days after FDA acceptance of BLA for INO-3107, whichever is earlier.
- Series B Warrants: Expire five years from the date of issuance.
- Underwriter: Piper Sandler & Co. acting as representative for several underwriters.
- Closing Date: Expected on or about July 7, 2025.
Inovio Pharmaceuticals, Inc. held its 2025 Annual Meeting of Stockholders on May 20, 2025. The meeting resulted in the election of eight directors and the ratification of Ernst & Young LLP as the independent auditor.
🚩 Red Flags
- High number of Broker Non-Votes (10,956,881 shares) across all proposals, indicating a significant portion of voting power was not exercised or directed by brokers.
📋 Key Facts
- Annual Meeting held on May 20, 2025.
- Quorum reached with 20,020,605 shares present or represented (54.59% of total common stock).
- Eight directors were elected to serve until the 2026 Annual Meeting.
- Ernst & Young LLP was ratified as independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- Shareholders approved compensation of NEOs on a non-binding advisory basis.
- Shareholders approved amendment and restatement of the 2023 Omnibus Incentive Plan.
Inovio Pharmaceuticals, Inc. has filed an 8-K to furnish its quarterly financial results for the period ended March 31, 2025.
📋 Key Facts
- Reporting date of event: May 13, 2025
- The filing pertains to the quarter ended March 31, 2025
- Financial results were announced via press release (Exhibit 99.1)
Inovio Pharmaceuticals, Inc. has filed an 8-K to furnish its financial results for the quarter and full year ended December 31, 2024.
📋 Key Facts
- The filing reports on financial results for the period ending December 31, 2024.
- Results were announced via press release on March 18, 2025.
- Information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 liability.
Inovio Pharmaceuticals entered into an underwriting agreement to conduct a public offering of 10,000,000 shares of common stock and 10,000,000 warrants. The offering is priced at $3.00 per share/warrant unit, intended to raise approximately $27.6 million in net proceeds.
🚩 Red Flags
- Significant dilution: Issuance of 10 million new shares plus 10 million warrants will substantially dilute existing shareholders.
- Warrant overhang: The issuance of a large number of warrants (1:1 ratio to shares) creates significant future dilution potential.
📋 Key Facts
- Offering size: 10,000,000 shares of common stock and 10,000,000 warrants.
- Pricing: $3.00 per share and accompanying warrant.
- Warrant terms: Exercise price of $3.76 per share; five-year expiration.
- Expected net proceeds: Approximately $27.6 million after expenses and commissions.
- Underwriters: Oppenheimer & Co. Inc. and Citizens JMP Securities, LLC.
- Closing date: Expected December 16, 2024.
Inovio Pharmaceuticals, Inc. issued an 8-K to furnish its quarterly financial results for the period ending September 30, 2024. The filing serves as a formal announcement of the company's recent operational and financial performance.
📋 Key Facts
- Report date: November 14, 2024
- Reporting period: Quarter and nine months ended September 30, 2024
- The filing includes a press release (Exhibit 99.1) detailing financial results.
- Information is furnished under Item 2.02 and not 'filed' for purposes of Section 18 liability.
Inovio Pharmaceuticals entered into an Equity Distribution Agreement with Oppenheimer & Co. Inc. to facilitate the sale of common stock via an 'at-the-market' (ATM) offering. The agreement allows for the potential issuance of up to $60,000,000 in aggregate gross proceeds.
🚩 Red Flags
- Potential for significant shareholder dilution through the issuance of new common stock.
- ATM offerings are often used by micro-cap biotech companies to raise immediate working capital, which can signal a need for cash to fund ongoing operations.
📋 Key Facts
- Date of Agreement: August 13, 2024
- Sales Agent: Oppenheimer & Co. Inc.
- Maximum Aggregate Offering Price: Up to $60,000,000
- Commission Rate: Up to 3.0% of gross sales proceeds
- Offering Method: At-the-market (ATM) offering under Rule 415(a)(4)
- Registration Basis: Previously filed and effective Form S-3 (File No. 333-275445)
Inovio Pharmaceuticals, Inc. filed an 8-K to furnish its quarterly financial results for the period ending June 30, 2024. The filing serves as a formal announcement of the company's recent earnings performance.
📋 Key Facts
- Report date: August 8, 2024
- Reporting period: Quarter and six months ended June 30, 2024
- The filing includes Exhibit 99.1 containing the press release of financial results.
- Information is furnished under Item 2.02 but not 'filed' for purposes of Section 18 liability.
Inovio Pharmaceuticals announced the granting of performance-based restricted stock units (PSUs) to its named executive officers and reported results from its 2024 Annual Meeting of Stockholders. The meeting saw the election of eight directors and the ratification of Ernst & Young LLP as independent auditors.
🚩 Red Flags
- Low shareholder turnout at the annual meeting (49.74% participation).
📋 Key Facts
- Granted PSU Awards to CEO Jacqueline E. Shea (33,200 units), CFO Peter D. Kies (8,900 units), and CSO Laurent M. Humeau (8,900 units).
- 70% of PSUs are tied to milestones for lead product candidate INO-3107, including FDA approval, US commercial launch, market share, and net sales targets with deadlines between end of 2025 and end of 2027.
- 30% of PSUs are tied to Relative Total Shareholder Return (TSR) against the Russell 2000 Biotechnology Subsector index for the period June 1, 2024 – Dec 31, 2027.
- The 2024 Annual Meeting saw a quorum of 49.74% (11,625,442 shares) present or represented by proxy.
- Eight directors were elected to serve until the 2025 Annual Meeting.
Inovio Pharmaceuticals, Inc. filed an 8-K to furnish its quarterly financial results for the period ended March 31, 2024. The filing serves as a formal announcement of the company's recent earnings release.
📋 Key Facts
- Report date: May 13, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition)
- Financial results were released via press release dated May 13, 2024 (Exhibit 99.1)
Inovio Pharmaceuticals entered into an underwriting agreement for a registered direct offering of common stock and pre-funded warrants. The offering aims to raise approximately $33.2 million in net proceeds.
🚩 Red Flags
- Significant dilution for existing shareholders due to the issuance of both new common stock and a large number of pre-funded warrants (nearly equal to the share count).
- Pre-funded warrants allow investors to bypass certain ownership thresholds, potentially concentrating voting power.
📋 Key Facts
- Offering type: Registered direct offering (underwritten).
- Shares to be issued: 2,536,258 shares of common stock at $7.693 per share.
- Warrants to be issued: Up to 2,135,477 pre-funded warrants at a price of $7.692 per warrant.
- Expected net proceeds: Approximately $33.2 million after discounts and expenses.
- Underwriters: Oppenheimer & Co. Inc. and Citizens JMP Securities, LLC.
- Anticipated closing date: April 18, 2024.
Inovio Pharmaceuticals, Inc. has implemented a 1-for-12 reverse stock split effective January 24, 2024. This action combines every 12 existing shares into one single share of common stock.
🚩 Red Flags
- Reverse stock split: Often used by micro-cap/biotech companies to boost share price to meet minimum exchange listing requirements (Nasdaq).
- Potential signal of significant equity dilution or downward pressure on share price prior to the split.
📋 Key Facts
- Reverse stock split ratio: 1-for-12
- Effective date/time: 5:00 p.m. ET on January 24, 2024
- Fractional shares were not issued; instead, stockholders received a proportional cash payment based on the closing price on Nasdaq.
- The par value per share remains unchanged at $0.001.
- Authorized shares remain at 600,000,000.
Inovio Pharmaceuticals, Inc. announced that stockholders approved a proposal to authorize the Board of Directors to effect a reverse stock split at any time within one year of the meeting. The split ratio is proposed to range from 1-for-10 to 1-for-50.
🚩 Red Flags
- Reverse stock split authorized: Typically used to boost share price to meet minimum exchange listing requirements or to improve market perception.
- Significant 'Against' vote: Approximately 29.6% of present/represented shares voted against the reverse split, indicating substantial shareholder opposition.
📋 Key Facts
- Special Meeting held on January 12, 2024.
- Stockholders approved a reverse stock split proposal (Proposal 1).
- The authorized ratio for the reverse split ranges from 1-for-10 to 1-for-50.
- Approval is valid for up to one year from the date of the Special Meeting.
- Voting results: Proposal 1 received 96,534,629 votes 'For', 48,857,255 'Against', and 874,089 'Abstain'.
- Quorum was met with 146,265,973 shares (53.6% of total shares entitled to vote) represented at the meeting.